Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is a reason why certain beginning investors are conned if they run with that frame of mind.
Complete BS. Anyone can write an article for Seeking Alpha. Absolutely anyone regardless of background or lack thereof. There are no independent investment analysts that cover ELTP and there will probably never be.
Reformulate again? As in 3 strikes and your out? SequestOx is toast.
I would expect approval closer to December 2018.
Lol I would love to see you present a situation when the FDA changed their mind on previously agreed upon topline BE results. Not gonna happen.
Funny thing is that Nasrat said Puracap was waiting on SequestOx BE results. That waiting is only going to continue on like the Energizer Bunny since the SequestOx program was stopped.
Good thing no one can stop Nasrat...other than facts and science.
Generic Perc this quarter will not happen.
I wouldn't put a dollar sign next to those drugs. It would be more applicable to use a penny sign.
"We were hoping for better and more decisive results for the reformulated immediate release version of SequestOx."
1.2 hour Tmax beyond Roxicodone. The tech simply doesn't work. The key objective was not met and per Nasrat, "the company will not proceed with the rest of the clinical trials"
SequestOx is a dead fish under Nasrat's management and has been for the past few years once the Tmax surprise news rose to the surface.
Probably better than the Oxy launched with Epic.
They buy blockbuster Trimipramine to save the day.
Please stop posting. This is pure trash. Can't even be considered fake news it is so far from reality.
SequestOx is an Immediate Release drug. This is for people in serious pain (e.g., right after surgery) that need the pain resolved pronto and a shorter Tmax profile. Not the case here despite what a few here want you to believe.
Any investor knows that history is just that, history and nothing more. Lol As I said, which are we closer to? Oh, that's right: $0.02. Case closed.
Please remind me how he is cashing out? Oh that is right increases in salary & side deals. This is the equivalent of cashing out of worthless stock so he doesn't leave empty handed.
Much closer to 0.02 than 0.35 by a mile.
Buy everything under 0.35. Lol
Winner winner chicken dinner! Opiate crisis going on and ELTP's stock has tanked hard. With this news there should be a lift in the stock - rising tide lifts all ships in the industry. Not the case and further emphasizes reality of Elite's pipeline.
You are right. It has quickly become a shotgun approach and strategically analyzing if any of the crap thrown at the walls will stick.
And yet it all means nothing until Elite gets at least one ADT product FDA approved.
J-o-k-e Nothing ever published on this company has ever been remotely accurate.
No, it is not $2.10 or anything remotely close for that matter. SequestOx was baked in at that point, which is now worthless.
That is the most ridiculous investing advice.
The split of product ownership is similar to the first deal, if I remember right. To your point, we have zero insight into the markets or realistic penetration to perform any sort of analysis or value add to the company. This is an ongoing saga of a waiting game.
But what about the romantic wining & dining from Puracap?! They own 69% of the Chinese opiate market! More like Pura-crapped all over Elite with SequestOx turd.
The flex workforce is not what you think. It is "flex" as in flex down due to not having the sales ramp up they expected on positive BE results of SequestOx. This is wording to ensure the employee understands the situation and uncertain of ability to work full time hours.
I beg to differ. Trimipramine and products the company is currently selling are more like foul outs than singles.
Are you sure the 10-12 month estimated window refers to ADT tech? Might want to look a little deeper.
A dollar?! Based on what rainbows and butterflies?
In other words, "pause permanently".
Did you see today's spike?! Fake news.
What he has never done is say the market that is expected to be captured. Always leaves it up to the consulting experts without details. That means the proof is in the pudding and real results need to be had. I have seen stocks crash on FDA approval when the stock converts from FDA anticipated approval to show-me results, which are much more difficult. We can't even get an approval.
Lawyers tend to have a strong command of technical language, written & spoken. The words he uses aren't lies, but rather lead investors to believe one definition, when another definition is more plausible. A lack of live Q&A prevents real dialogue and follow up questions to get clarity for investors, which is clearly what the CEO does not want.
Stop it. Trimipramine is going to have killer sales.
Their hiring has done nothing for Elite. Nothing. It shows he can surround himself with whoever he wants and still end up in the same place, except with a few more self deals under his belt with ratchetable options.
I don't care where Nasrat has worked - the company has gone nowhere. It has a pipeline of "potential" products in the ANDA space assuming approval one day battling against multiple competitors.
This argument isn't worth a minute of my time. That logic is completely defunct. If tech was proven we would have an approval. If so, where is it?
Tech validation would lead to a much higher valuation. The stock price today doesn't include tech validation for the entire ER pipeline and fails to agree with your point.
Perhaps, but I wouldn't count on it changing. There is no evidence that leads to anything else. It would be interesting to see other programs that have been halted and picked back up after FDA conversations. It is not improbable, but my not be far from it.
Nasrat will say nothing until he gravels at the feet of the FDA and gets the final nail in the coffin. This buys him a little more time in hopes an ER approval takes place where SeauestOx will be old news and slip off into the night.
"Too smart and experienced"? His experience as CEO so far has shown nothing but the opposite. Or are you relating his "smartness" to how he gets the Board to buy off crappy one-off deals with Mikah where the only winner is himself?